Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19; Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone
Benzinga Newsdesk